ebola
viru
ebov
infect
human
nonhuman
primat
often
associ
high
morbid
mortal
rate
well
sever
hemorrhag
fever
ebov
biosafeti
pathogen
transmit
contact
bodili
fluid
fomit
droplet
infect
patient
ebov
consid
signific
threat
public
health
global
secur
due
potenti
use
bioweapon
current
fdaapprov
vaccin
therapeut
agent
avail
support
care
remain
standard
ebola
viru
diseas
evd
treatment
therefor
acceler
effort
develop
therapeut
key
object
ebov
research
commun
especi
sinc
evd
epidem
western
africa
drug
discoveri
develop
requir
consider
time
resourc
identifi
effect
drug
progress
clinic
trial
result
research
investig
repurpos
drug
addit
indic
becom
increasingli
preval
acceler
identif
therapeut
drug
evd
offlabel
use
fdaapprov
drug
particularli
advantag
safeti
concern
ethic
problem
alreadi
address
effect
identifi
potenti
compound
interest
larg
librari
chemic
compound
share
reliabl
reproduc
data
laboratori
provid
data
intern
commun
appropri
method
model
need
establish
furthermor
model
evalu
determin
predict
identifi
compound
like
efficaci
human
evd
indic
efficaci
could
includ
success
treatment
surviv
patient
allevi
diseas
sever
mitig
clinic
symptom
associ
ebov
infect
varieti
method
avail
measur
antivir
activ
vitro
howev
develop
screen
assay
detect
compound
antiebov
activ
previous
limit
due
difficulti
develop
suitabl
highthroughput
screen
system
biosafeti
viral
pathogen
classic
method
evalu
drug
efficaci
includ
reduct
viru
yield
decreas
viral
rna
transcript
determin
realtim
polymeras
chain
reaction
pcr
recent
therapeut
screen
method
transit
classic
method
measur
viral
inhibit
assay
abil
autom
result
higherthroughput
assay
chemistri
develop
enabl
homogen
measur
varieti
differ
endpoint
cytopath
effect
viral
protein
report
gene
express
serv
marker
viral
replic
grow
interest
identifi
drug
activ
ebov
result
varieti
assay
readout
activ
well
cytotox
use
cellbas
assay
highthroughput
screen
compound
librari
increas
steadili
recent
year
cellbas
assay
monitor
specif
viral
protein
provid
mean
screen
potent
viral
inhibitor
intracellularli
assay
identifi
drug
candid
desir
pharmacolog
properti
primari
drugdiscoveri
pipelin
studi
suscept
ebov
use
immort
cell
line
primari
monocytederiv
macrophag
mdm
investig
varieti
condit
differ
multipl
infect
moi
time
exposur
cell
passag
number
cellbas
assay
ebov
antibodi
use
detect
infect
cell
fluoresc
chemiluminesc
readout
use
determin
signaltonois
sn
ratio
highcont
imag
system
appli
determin
percentag
ebovposit
cell
toremifen
citrat
world
health
organ
consid
evalu
clinic
trial
treatment
evd
chosen
posit
control
measur
ebov
inhibit
condit
condit
drug
test
influenc
appar
potenc
test
drug
world
health
organ
commun
receiv
mani
request
repeat
experi
specif
condit
confirm
activ
identifi
anoth
laboratori
result
data
set
indic
variabl
valu
vari
assay
condit
data
present
provid
insight
differ
assay
paramet
impact
vitro
efficaci
potenti
antiebov
antivir
use
toremifen
citrat
model
compound
vero
african
green
monkey
kidney
atcc
cell
obtain
american
type
cultur
collect
manassa
va
vero
cell
african
green
monkey
kidney
work
cell
bank
obtain
bei
resourc
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
manassa
va
huh
cell
human
hepatocellular
carcinoma
obtain
dr
hideki
ebihara
niaid
rocki
mountain
laboratori
hamilton
mt
cell
line
maintain
integr
research
facil
irf
follow
cell
sourc
instruct
primari
vero
huh
cell
cultur
grown
confluenc
fisher
scientif
tripl
layer
tissu
cultur
flask
nunc
contain
dulbecco
modif
eagl
medium
dmem
gibco
supplement
heatinactiv
fetal
bovin
serum
fb
sigma
cell
dispers
trypsin
gibco
treatment
reseed
secondari
cultur
process
remov
cell
primari
cultur
dilut
transfer
secondari
cultur
constitut
passag
cell
line
provid
passag
point
new
cultur
introduc
previou
passag
seri
end
addit
cell
cultur
requir
least
viabl
order
achiev
accept
criteria
plate
use
screen
assay
gener
mdm
describ
previou
studi
briefli
pbmc
isol
human
whole
blood
densitygradi
centrifug
histopaqu
gml
sigmaaldrich
st
loui
mo
monocyt
purifi
use
human
microbead
miltenyi
biotec
san
diego
ca
follow
manufactur
instruct
monocyt
differenti
mdm
cultur
day
recombin
human
macrophag
colonystimul
factor
biotechn
minneapoli
mn
condit
medium
cell
kind
gift
dr
atsunobu
hiraoka
scgf
research
laboratori
kyoto
jp
media
replac
everi
day
incub
total
day
cell
harvest
plate
desir
plate
day
prior
drug
screen
assay
differenti
mdm
character
flow
cytometri
assay
initi
toremifen
citrat
oral
solut
test
studi
purchas
sigmaaldrich
ca
makona
isol
ebov
h
ebovmak
genbank
access
kind
gift
dr
gari
p
kobing
public
health
agenc
canada
winnipeg
ca
use
studi
gener
viru
stock
ebovmak
inocul
moi
vero
cell
bei
resourc
manassa
va
catalog
cytopath
effect
visibl
day
infect
monolay
show
cpe
cell
cultur
supernat
harvest
clarifi
centrifug
ebovmak
titer
determin
plaqu
assay
vero
cell
viru
titer
measur
use
serial
dilut
cultur
supernat
triplic
infect
vero
cell
monolay
plate
incub
h
plate
rock
everi
minut
ml
medium
contain
mem
gibco
avicel
fmc
biopolym
antibioticantimycot
gibco
ad
well
day
postincub
viru
plaqu
stain
crystal
violet
ricca
chemic
neutral
buffer
formalin
thermo
scientif
infect
titer
measur
plaqu
form
unit
per
ml
pfuml
procedur
use
live
ebov
perform
biosafeti
condit
vero
huh
cell
seed
overnight
cell
per
well
mdm
cell
plate
cell
per
well
dulbecco
modifi
eagl
medium
fetal
bovin
serum
black
opaqu
thermo
fisher
scientif
waltham
corn
clear
bottom
greiner
micropl
greiner
bioon
monro
nc
ebovmak
isol
dilut
cultur
media
specifi
moi
titer
use
determin
moi
herebi
gener
vero
cell
plate
cell
infect
transfer
ebovmak
isol
viru
dilut
plate
cell
plate
use
liquid
rainin
instrument
oakland
ca
cell
incub
indic
period
time
plate
fix
ad
neutralbuff
formalin
final
concentr
h
postinocul
hpi
fix
h
plate
transfer
lab
antibodi
stain
describ
previous
briefli
ebov
detect
exposur
infect
fix
permeabil
cell
monoclon
mous
antibodi
specif
ebov
matrix
protein
made
us
armi
medic
research
institut
infecti
diseas
frederick
md
center
diseas
control
prevent
contract
follow
stain
goat
antimous
igg
heavi
light
chain
antibodi
life
technolog
carlsbad
ca
h
fluoresc
quantifi
use
tecan
plate
reader
tecan
us
morrisvil
nc
highcont
imag
hci
system
operetta
perkinelm
waltham
hci
imag
collect
magnif
use
field
view
well
quantifi
percent
ebovposit
cell
viabil
cell
layer
monitor
stain
cell
nuclei
hoechst
dye
molecular
probe
h
columbu
softwar
perkinelm
use
analyz
hci
data
chemiluminesc
enzymelink
immunosorb
assay
celia
perform
detect
ebov
antiebov
antibodi
follow
stain
horseradish
peroxidas
hrp
conjug
goat
antimous
secondari
antibodi
seracar
milford
cat
chemiluminesc
quantifi
use
pico
chemiluminesc
substrat
thermo
fisher
scientif
inc
rockford
il
plate
reader
tecan
vero
huh
mdm
cell
seed
describ
media
overnight
compound
dimethyl
sulfoxid
predilut
reduc
dimethyl
sulfoxid
concentr
lower
compound
predilut
dilut
block
perform
final
dilut
transfer
compound
cell
plate
contain
cell
cultur
media
dilut
achiev
desir
compound
concentr
cell
cultur
media
process
perform
drug
screen
assay
shown
fig
three
plate
set
per
experi
two
plate
clear
bottom
greiner
micropl
detect
inhibit
ebov
one
mock
plate
black
opaqu
plate
determin
drug
cytotox
h
predilut
transport
laboratori
viru
mock
control
desir
moi
ad
cell
hpi
assay
plate
fix
final
concentr
nbf
h
transfer
lab
stain
infect
cell
detect
describ
confirm
accuraci
assay
high
background
chemiluminesc
assay
perform
afterward
cytotox
mock
infect
cell
plate
measur
h
treatment
compound
use
celltit
glo
luminesc
cell
viabil
assay
kit
accord
manufactur
instruct
promega
madison
wi
luminesc
read
tecan
plate
reader
fig
nonlinear
regress
analysi
curv
fit
paramet
perform
calcul
cytotox
concentr
graphpad
softwar
la
jolla
ca
use
doserespons
curv
compound
toremifen
citrat
error
bar
doserespons
curv
repres
standard
deviat
three
replic
equat
ratio
sn
percentag
ebovposit
infect
cell
z
factor
defin
previous
use
paramet
assay
valid
qualiti
control
cellbas
assay
repres
z
factor
defin
equat
z
sdpo
sdneg
imeanposimeanneg
assay
z
criteria
follow
z
correspond
excellentassay
z
correspond
suboptim
assay
z
correspond
unsuccess
assay
suscept
ebov
infect
evalu
multipl
cell
type
cellbas
assay
measur
antiebov
activ
vero
huh
mdm
cell
infect
ebovmak
isol
differ
moi
assay
termin
hpi
cell
stain
fluoresc
antibodi
hoechst
dye
use
visual
cell
nuclei
infect
measur
use
highcont
imag
hci
system
percentag
posit
cell
growth
ebovmak
isol
three
cell
type
compar
time
vero
cell
ebov
spread
slightli
slower
number
posit
cell
overal
lower
compar
huh
cell
fig
mdm
suscept
ebov
among
cell
type
hpi
mdm
alreadi
exhibit
typic
dose
respons
rel
viru
input
minim
ebov
replic
observ
vero
huh
cell
hpi
moi
test
viru
spread
effect
hpi
higher
moi
vero
huh
cell
moi
mdm
fig
infect
mdm
satur
hpi
almost
moi
fig
nuclear
stain
cell
type
show
cell
layer
deterior
increas
viru
inoculum
durat
infect
clearli
evid
hpi
time
point
higher
viru
input
moi
fig
cell
layer
frequent
becam
fragil
later
time
point
cell
layer
would
lift
well
surfac
possibl
increas
exposur
viru
higher
moi
manipul
plate
fixingstain
procedur
fig
hci
system
prove
invalu
determin
optim
assay
condit
end
point
viru
input
identifi
potenti
issu
cell
layer
integr
differ
viru
input
endpoint
assess
identifi
accept
rang
test
drug
vero
huh
cell
tabl
experiment
plate
fig
use
analysi
fluoresc
sn
ratio
calcul
use
tecan
plate
reader
percentag
ebovposit
cell
determin
use
hci
reproduc
data
determin
percentag
ebovposit
cell
kept
within
rang
sn
ratio
lower
sn
ratio
lower
percentag
infect
cell
distinguish
activ
drug
nonact
becom
increasingli
difficult
hand
higher
sn
ratio
cell
infect
rate
trend
toward
cell
overgrow
later
time
point
risk
disrupt
cell
layer
greater
cell
layer
disrupt
increas
variabl
assay
therefor
optim
assay
condit
ie
durat
infect
viru
input
care
calibr
result
compromis
signal
strength
cell
viabil
base
data
obtain
fig
tabl
two
optim
condit
fluoresc
assay
select
moi
hpi
endpoint
moi
endpoint
hpi
produc
robust
signal
cell
type
vero
huh
mdm
fig
tabl
vero
cell
infect
ebov
around
mdm
huh
cell
usual
stronger
signal
around
higher
ebovposit
cell
fig
two
condit
similar
signal
ebov
infect
rate
lower
moi
accept
signal
observ
hpi
cell
inocul
higher
moi
infect
time
accept
signal
could
reduc
h
assay
develop
phase
vero
cell
appear
less
reliabl
produc
consist
viral
spread
lack
reliabl
appear
due
cell
cultur
passag
histori
address
matter
vero
cell
analyz
differ
cell
passag
number
determin
percentag
ebovposit
cell
fig
cell
type
infect
moi
h
viral
spread
huh
cell
consist
cell
cultur
passag
indic
passag
number
impact
ebov
spread
huh
cell
rang
test
contrast
ebov
spread
vero
cell
vari
consider
cell
passag
peak
infect
replic
efficaci
cell
cultur
passag
fig
equal
lower
earli
late
passag
signific
differ
observ
passag
compar
passag
use
ordinari
oneway
anova
follow
dunnett
multipl
comparison
graphpad
prism
occasion
except
trend
observ
fig
infect
ebov
vero
huh
cell
compar
earli
late
passag
number
rang
moi
h
case
vero
cell
test
later
passag
show
lower
infect
rate
expect
earli
passag
demonstr
unusu
high
infect
rate
infect
huh
cell
remain
consist
regardless
passag
number
vero
cell
inconsist
overal
despit
trend
origin
observ
viru
input
durat
experi
impact
drug
activ
address
evalu
vitro
efficaci
toremifen
citrat
fdaapprov
drug
proven
antiebov
activ
differ
paramet
use
fluoresc
read
huh
cell
infect
constant
moi
treat
toremifen
citrat
h
fig
later
time
point
result
decreas
activ
hpi
higher
hpi
time
point
remain
constant
hpi
activ
toremifen
citrat
increas
viru
input
decreas
moi
fig
moi
lower
moi
addit
time
viru
input
cell
type
use
assay
result
differ
calcul
antiebov
activ
toremifen
citrat
measur
use
variabl
assay
endpoint
hpi
moi
cell
line
vero
huh
cell
fig
valu
toremifen
citrat
increas
exposur
time
viru
input
cell
type
overal
activ
vero
cell
higher
maximum
activ
hpi
moi
huh
cell
maximum
activ
detect
hpi
moi
valu
toremifen
citrat
increas
exposur
time
viru
input
cell
type
indic
drug
requir
produc
antiebov
effect
increas
sensit
drug
screen
assay
chemiluminesc
enzymelink
immunosorb
assay
celia
develop
evalu
compound
antiebov
activ
celia
combin
advantag
specif
immunoassay
high
sensit
chemiluminesc
enzym
detect
assay
simpl
low
cost
screen
assay
celia
compar
fluoresc
assay
detect
regular
plate
reader
hci
system
test
efficaci
toremifen
citrat
ebov
infect
huh
cell
rang
moi
three
differ
time
point
hpi
assay
paramet
signaltonois
sn
z
factor
compar
assay
tabl
earliest
time
point
hpi
celia
higher
sensit
fluoresc
detect
assay
z
accept
rang
even
lowest
moi
contrast
fluoresc
assay
requir
higher
moi
reliabl
data
set
z
hpi
time
point
detect
method
gener
high
qualiti
data
set
celia
provid
improv
z
factor
hpi
celia
fluoresc
assay
also
produc
excel
data
use
hci
detect
fluoresc
data
detect
regular
plate
reader
show
higher
variabl
mayb
due
cytopath
effect
determin
data
set
accept
z
overal
good
correl
differ
detect
method
tabl
detect
assay
demonstr
higher
moi
longer
time
exposur
led
increas
valu
toremifen
citrat
contrast
valu
show
consider
lower
fluctuat
differ
condit
test
establish
celia
use
compar
antiebov
activ
toremifen
citrat
differ
cell
type
vero
huh
mdm
use
moi
time
point
h
fig
huh
cell
mdm
sn
ratio
rang
z
factor
gener
fig
sn
vero
cell
rang
lead
variabl
reflect
wider
rang
z
factor
fig
activ
toremifen
compar
consider
differ
detect
cell
type
fig
efficaci
toremifen
citrat
higher
huh
cell
mdm
higher
vero
cell
fig
summari
chemiluminesc
drug
screen
assay
evalu
antiebov
activ
compound
robust
reliabl
reproduc
method
data
present
studi
exemplifi
import
guidelin
test
drug
vitro
antivir
activ
gener
reproduc
data
set
share
confirm
outsid
laboratori
sever
paramet
consid
test
drug
vitro
antivir
efficaci
cell
type
assay
endpoint
viru
input
among
import
factor
vero
cell
line
deriv
immort
african
green
monkey
kidney
cell
commonli
use
cell
line
test
antivir
filovirus
ebov
propag
well
cell
line
mani
laboratori
includ
gener
viru
stock
determin
viru
titer
vero
cell
howev
argument
use
cell
line
relev
human
diseas
come
repeatedli
henc
human
liver
cancer
cell
line
huh
human
mdm
chosen
studi
macrophag
relev
human
diseas
consid
play
import
role
viru
dissemin
pathogenesi
evd
therefor
drug
highli
effect
inhibit
ebov
infect
mdm
may
better
translat
vivo
potenc
vero
cell
suscept
three
cell
type
compar
rang
viru
input
time
cell
type
permiss
ebov
infect
differ
degre
mdm
demonstr
optim
replic
start
earli
hpi
moi
contrast
ebov
grew
slower
vero
huh
cell
optim
condit
evalu
drug
efficaci
use
fluoresc
assay
moi
h
time
point
moi
h
time
point
cell
type
ensur
strong
viru
signal
avoid
destruct
cell
layer
fig
howev
moi
suitabl
detect
inhibitor
later
step
viru
lifecycl
abil
detect
inhibitor
viru
assembl
egress
reduc
increas
moi
higher
proport
cell
infect
even
presenc
drug
reason
would
advis
use
lower
moi
inhibit
viru
spread
within
cultur
detect
though
vero
cell
one
broadli
use
cell
line
test
compound
vitro
assay
data
show
perform
cell
ideal
especi
evalu
drug
antiebov
activ
although
never
good
idea
passag
cell
long
found
lower
higher
passag
vero
cell
show
decreas
percentag
ebovposit
cell
huh
cell
show
effici
reliabl
viru
replic
irrespect
passag
number
immort
cancer
cell
line
gener
easi
choic
vitro
drug
test
easi
handl
propag
expand
plate
weekbyweek
basi
rel
consist
contrast
primari
cell
type
human
primari
macrophag
prolifer
cell
cultur
ideal
gener
fresh
human
blood
upon
use
larg
scale
test
procur
blood
volum
need
gener
mdm
cumbersom
isol
techniqu
could
challeng
mdm
demonstr
effici
spread
viru
cell
cultur
time
donortodonor
variabl
preclud
consist
gener
macrophag
differ
donor
pool
despit
constraint
test
select
drug
closer
human
clinic
studi
human
macrophag
make
sens
get
better
idea
efficaci
relev
target
cell
fluoresc
detect
two
differ
read
out
techniqu
advantag
plate
reader
measur
averag
fluoresc
across
whole
well
read
quick
conduc
handl
larg
number
plate
screen
howev
qualiti
cell
layer
monitor
hci
provid
imag
field
well
nuclear
stain
ad
parallel
indic
viabil
cell
layer
assay
develop
phase
tool
especi
use
identifi
condit
ensur
healthi
cell
layer
identifi
issu
plate
corner
edg
effect
assay
qualiti
control
one
drawback
whole
well
imag
certain
number
field
insid
well
import
pick
field
wise
avoid
bia
skew
data
scan
least
field
per
well
recommend
statist
purpos
increas
read
time
per
plate
time
read
analyz
hci
data
take
consider
longer
data
acquir
regular
plate
reader
hci
measur
differ
paramet
percentag
ebovposit
cell
mean
signal
intens
per
cell
regular
plate
reader
hci
uniqu
applic
drug
test
program
plate
reader
good
quick
readout
larg
number
plate
hci
system
use
cross
check
qualiti
cell
clarifi
issu
nois
signal
variabl
addit
fluoresc
assay
also
implement
celia
use
hrplabel
antibodi
amplifi
signal
increas
sensit
viru
detect
expect
celia
show
improv
qualiti
data
set
compar
fluoresc
assay
sn
ratio
z
factor
accept
rang
earli
hpi
lowest
viru
input
detect
moi
could
also
determin
time
point
hpi
two
fluoresc
read
out
similar
chemiluminesc
read
toremifen
citrat
select
estrogen
receptor
modul
report
activ
vivo
ebov
mice
fdaapprov
drug
treat
breast
cancer
mechan
action
studi
show
toremifen
citrat
affect
ebov
viru
entri
stage
virusfus
endosom
membran
toremifen
citrat
chosen
potenti
candid
clinic
evalu
evd
patient
evalu
perform
toremifen
citrat
antiebov
activ
use
differ
condit
trend
toward
higher
increas
input
viru
longer
assay
time
observ
data
indic
amount
viru
present
cell
tissu
high
enough
drug
less
activ
also
longer
time
viru
replic
drug
may
unabl
stem
high
viral
replic
contrast
valu
less
affect
high
moi
longer
time
point
may
therefor
reliabl
paramet
compar
data
set
laboratori
serum
media
pretreat
cell
compound
also
consider
effect
antivir
activ
toremifen
compar
directli
brincidofovir
panel
differ
condit
show
activ
brincidofovir
depend
media
condit
low
serum
h
pretreat
ad
viru
contrast
serum
concentr
effect
activ
toremifen
citrat
pretreat
cell
h
instead
h
decreas
activ
drug
mani
report
repurpos
fdaapprov
drug
discuss
compar
drug
vitro
determin
cell
cultur
maximum
concentr
human
plasma
determin
clinic
trial
evalu
potenti
drug
vivo
activ
howev
data
show
drug
rang
log
base
test
condit
eg
moi
time
endpoint
serum
johanson
et
al
report
toremifen
two
differ
ebov
strain
ebovkik
ebovmay
respect
hpi
moi
celia
use
antibodi
data
compar
ebovmak
determin
assay
similar
condit
tabl
moi
hpi
understand
assay
perform
potenti
variabl
import
caution
use
use
vitro
data
make
decis
advanc
drug
vivo
studi
